<?xml version="1.0" encoding="UTF-8"?>
<p id="par0135">An important therapy in combating SARS-CoV-2 is a neutralizing antibody directed against the S protein of the virus (
 <xref rid="fig0005" ref-type="fig">Fig. 1</xref>). There exists a neutralizing monoclonal antibody directed against the Ras-binding domain of the S protein of MERS-CoV, suggesting the potential to discover a similar antibody for SARS-CoV-2 
 <xref rid="bib0380" ref-type="bibr">[76]</xref>. There have been promising preliminary results for tocilizumab, a monoclonal antibody against the IL-6 receptor, but more work is necessary to understand the safety and efficacy of the antibody 
 <xref rid="bib0170" ref-type="bibr">[34]</xref>. The development of neutralizing antibodies poses an issue in rapid treatment strategy, as traditional screen options may be too slow for the pandemic to ensure sufficient breadth of treatment 
 <xref rid="bib0375" ref-type="bibr">[75]</xref>.
</p>
